Compounded Semaglutide Guide
Safety, Dosing & Pharmacies
Complete guide to compounded semaglutide. Learn about safety, how to find reputable pharmacies, dosing, and what to watch out.
What Is Compounded Semaglutide?
Compounded semaglutide is the same active molecule as Ozempic and Wegovy, but prepared by licensed compounding pharmacies rather than Novo Nordisk.
Why it exists: The FDA allows compounding during drug shortages. Since Ozempic and Wegovy have been on the shortage list, compounding pharmacies can legally produce semaglutide.
Key difference: Compounded medications are NOT FDA-approved. They don't undergo the same testing and quality control as brand-name drugs. Quality depends entirely on the pharmacy.
503A vs 503B Pharmacies
Understanding Compounded Dosing
Compounded semaglutide typically comes in vials with a concentration (e.g., 2.5mg/mL or 5mg/mL). You'll draw up your dose using insulin syringes.
Example: From a 2.5mg/mL vial, to get 0.25mg dose, draw up 10 units (0.1mL). For 0.5mg, draw 20 units (0.2mL). For 1.0mg, draw 40 units (0.4mL).
Tip: Use Shotlee's peptide reconstitution calculator to verify your dosing calculations and track your vial usage.
Guide FAQs
Complete guide to compounded semaglutide. Learn about safety, how to find reputable pharmacies, dosing, and what to watch out.
Yes. Shotlee supports tracking Compounded Semaglutide doses, side effects, and health metrics. It is free to use.
Track Your Compounded Semaglutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
📚References & sources
Latest on Compounded Semaglutide
Obesity Drug Coverage Restrictions Force Patients to Pivot
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
5 min read
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
The Himsification of Medicine: Super Bowl Ad & Semaglutide Clash
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
4 min read